Initial Research
The epidemic of severe atypical pneumonia which was observed in the Chinese province of Guangdong and reported internationally on Feb- ruary 11, 2003 (WHO, WER 11/2003), was initially suspected to be linked to a newly emerging influenza virus: on February 19, 2003, researchers isolated an avian influenza A (H5N1) virus from a child in Hong Kong. This virus was similar to the influenza virus originating from birds that caused an outbreak in humans in Hong Kong in 1997, and new outbreaks of similar strains were expected. However, bird 'flu', possibly of poultry origin, was soon ruled out as the cause of the newly-termed Severe Acute Respiratory Syndrome, or SARS.
Investigations then focused on members of the Paramyxoviridae family, after paramyxovirus-like particles were found by electron microscopy of respiratory samples from patients in Hong Kong and Frankfurt am Main. Further investigations showed that human metapneumovirus (hMPV; van den Hoogen) was present in a substantial number of, but not in all, SARS patients reported at the time.
At about the same time, China reported the detection, by electron microscopy, of Chlamydia-like organisms in patients who had died from atypical pneumonia during the Guangdong outbreak. Again, this finding could not be confirmed by other laboratories in SARS patients from outside China.
- April 8-10
- April 12
- June 6
- August 14
- September 8
- September 24
- References
- 30 Virology
- Discovery of the SARS Virus
- Initial Research
- Coronaviridae
- SARS Co-V
- Genome Sequence
- Antiviral Agents and Vaccines
- Antiviral Drugs
- Vaccines
- Outlook
- References
- Routes of Transmission
- Patient Factors in Transmission
- Asymptomatic Patients
- Symptomatic Patients
- The Unsuspected Patients
- High-Risk Activities
- Transmission during Quarantine
- Introduction
- Global Spread
- Hong Kong
- Other Countries
- Eradication
- Outlook
- Introduction
- International Coordination
- Management of SARS in the post-outbreak period
- National Measures
- Legislation
- Quarantine after Discharge
- Infection Control in Healthcare Settings
- General Measures
- Protective Measures
- Special Settings
- Intensive Care Units
- Intubating a SARS Patient
- Anesthesia
- Triage
- Internet Sources
- After the Outbreak
- Conclusion
- 108 Case Definition
- WHO Case Definition
- Suspect case
- Reclassification of cases
- CDC Case Definition
- 112 Diagnostic Tests
- Introduction
- Laboratory tests
- Virus isolation
- Antibody detection
- Interpretation
- Limitations
- Biosafety considerations
- Clinical Presentation and Diagnosis
- Clinical Presentation
- Diagnosis
- Clinical Course
- Histopathology
- Lung Biopsy
- Postmortem Findings
- Discharge and Follow-up
- Psychosocial Issues
- References
- 144 SARS Treatment
- Antibiotic therapy
- Antiviral therapy
- Ribavirin
- Alternative medicine
- Immunomodulatory therapy
- Other immunomodulators
- Assisted ventilation
- Invasive mechanical ventilation
- Clinical outcomes
- Appendix 1
- A standardized treatment protocol for adult SARS in Hong Kong
- Appendix 2
- A treatment regimen for SARS in Guangzhou, China
- References
- 168 Pediatric SARS
- Clinical Manifestation